Ghana is to establish a private-sector-led medical tourism hub and invest US$1 billion in pharmaceutical and biomanufacturing, with the aim of producing up to 80% of the country’s essential medicines by 2030.
The proposals were announced by Finance Minister Cassiel Ato Forson when he presented the 2027 Budget to Parliament on Thursday, November 12. Health has been allocated GH¢40.3 billion in the budget.
The planned Ghana Medical Tourism Hub will bring together hotels, laboratories, pharmacies, specialist hospitals, diagnostic centres and rehabilitation services. The government will support the project with serviced land, trunk infrastructure and targeted tax incentives.
By 2030, the government expects the hub to increase the number of visitors, encourage longer stays and boost visitor spending and foreign-exchange earnings. The Budget Statement says the benefits should extend to Ghanaian farmers, food suppliers, transport operators, craftspeople, artists, technology companies and event businesses.
Pharmaceutical manufacturing
Ghana currently imports between 70 and 75% of the medicines it requires, at an annual cost of about US$500 million.
The US$1 billion pharmaceutical and biomanufacturing compact is intended to strengthen medicine supplies, create skilled industrial employment, reduce foreign-exchange pressures and establish Ghana as a pharmaceutical export base for West Africa.
Manufacturing hubs are planned for the Eastern and Central Regions. Qualified Ghanaian and foreign manufacturers will be able to access the sites through transparent leases and operating agreements.
Proposed changes to public procurement laws will require state-funded medicine purchases to favour Ghanaian-made products whenever local manufacturers can provide sufficient quantities and meet approved quality standards. Ghanaian medicines will therefore become the default choice for public medicine spending.
The Statement refers to India, Ethiopia, Nigeria and Tanzania, where local manufacturers already receive preference in public medicine procurement, but says Ghana intends to go further.
It also makes clear that the policy will not excuse poor quality, delayed deliveries or poor value. Suppliers must retain registration with the Food and Drugs Authority and comply with Good Manufacturing Practice standards. Manufacturers will receive support to pursue WHO prequalification.
A state-owned special purpose vehicle is expected to begin construction of the pharmaceutical hubs in 2027. The government’s 2030 target is for Ghana to produce between 60 and 80% of its essential medicines locally.
The plan also includes fully funding vaccines and essential medicines from 2030. This part of the programme is expected to create about 20,000 direct and indirect jobs.
In August 2026, Ghana signed an agreement with Africa Centres for Disease Control and Prevention under the Africa Pooled Procurement Mechanism. The arrangement gives Ghanaian manufacturers access to a continental market of about 1.4 billion people and follows calls for foreign investment in domestic medicine and vaccine production.
Details yet to be disclosed
The Budget Statement does not provide the cost, location or completion date for the medical tourism hub. It also gives no detailed breakdown of the US$1 billion pharmaceutical investment or the funding allocated to the hub.
The state-owned vehicle responsible for constructing the pharmaceutical hubs is not named. Apart from confirming that construction will start in 2027 and setting the 2030 production target, the Statement provides no further dates.